$TMO (Thermo Fisher Scientific, Inc.)

$TMO {{ '2016-07-28T15:21:26+0000' | timeago}} • Announcement

$TMO said its Life Sciences Solutions Segment revenue grew 13% to $1.28Bil in 2Q16 while Analytical Instruments Segment revenue increased 2% to $794MM. The largest Laboratory Products and Services Segment revenue grew 6% to $1.80Bil.

$TMO {{ '2017-07-19T12:44:47+0000' | timeago}} • Announcement

$TMO priced an offering of EUR2.6Bil of senior notes. The issuance of the notes is expected to close on or about July 24, 2017. $TMO plans to use all of net proceeds to fund a portion of consideration payable for its acquisition of Patheon, including the repayment of debt of Patheon to be assumed by $TMO, which is estimated to be about $7.2Bil.

$TMO {{ '2017-07-12T21:02:58+0000' | timeago}} • Announcement

$TMO declared a quarterly cash dividend of $0.15 per share, payable on October 16, 2017, to shareholders of record as of September 15, 2017.

$TMO {{ '2017-05-18T13:12:12+0000' | timeago}} • Announcement

$TMO declared a quarterly cash dividend of $0.15 per share. The dividend will be paid on July 17, 2017, to shareholders of record as of June 15, 2017.

$TMO {{ '2017-04-26T14:19:48+0000' | timeago}} • Webcast

For 2017, $TMO expects modest organic growth for its microarray business. The company said it has launched a number of products and commercial initiatives for that business and that will help build some momentum moving through the course of 2017.

$TMO {{ '2017-04-26T14:13:04+0000' | timeago}} • Webcast

$TMO said roughly half of the margin expansion within Analytical Instruments segment in 1Q17 came from FEI acquisition. There is a good volume pull through in that segment and expects to drive additional revenue using the PPI (practical process improvement) business system, added the company.

$TMO {{ '2017-04-26T11:16:21+0000' | timeago}} • Announcement

In 1Q17, $TMO's revenue from Life Sciences Solutions segment grew 12% to $1.36Bil, while that from Analytical Instruments segment grew 39% to $1.05Bil. In other segments, Specialty Diagnostics revenue grew 1% to $866MM, and Laboratory Products and Services revenue grew 3% to $1.70Bil.

$TMO {{ '2017-04-26T11:11:01+0000' | timeago}} • Announcement

$TMO raised its revenue guidance for FY17 to a new range of $19.51-19.71Bil vs its original guidance of $19.38-19.62Bil announced in January 2017. Adjusted EPS guidance was raised to a range of $9.12-9.28 vs the $9.06-9.24 previously communicated.

$TMO {{ '2017-04-26T11:06:50+0000' | timeago}} • Announcement

Biotechnology product development company $TMO posted 11% growth in revenue to $4.77Bil in 1Q17. Organic revenue growth was 4%. Net income was $551.4MM, or $1.40 per share, better than $402MM, or $1.01 per share in 1Q16. Excluding one-off costs, net income rose to $2.08 per share.

$TMO {{ '2017-04-20T13:38:59+0000' | timeago}} • Announcement

$TMO signed an agreement with the Institute of Medical Genetics and Pathology at University Hospital Basel, Switzerland. This agreement will establish the leading institution as the first partner in the Next Generation Sequencing Companion Dx Center of Excellence Program.

$TMO {{ '2017-03-08T12:59:38+0000' | timeago}} • Announcement

$TMO stated that it plans to use approx. $508MM of the net proceeds from the offering of senior notes due 2027 to redeem the outstanding $500MM aggregate principal amount of its 1.850% senior notes that mature on January 15, 2018. $TMO intends to use any remaining net proceeds for general corporate purposes.

$TMO {{ '2017-03-08T12:58:26+0000' | timeago}} • Announcement

$TMO has priced an offering of EUR500MM aggregate principal amount of 1.450% senior notes due 2027 at an issue price of 98.824% of the principal amount. The issuance is expected to close on or about March 16, 2017. The notes will pay interest on an annual basis.

$TMO {{ '2017-03-06T15:34:02+0000' | timeago}} • Announcement

$TMO acquired Core Informatics, which provides a cloud-based platform supporting scientific data management. Core's offerings will significantly enhance $TMO's existing informatics solutions and complement its cloud platform, which supports the company's genetic analysis, qPCR and proteomics systems.

$TMO {{ '2017-03-01T15:41:49+0000' | timeago}} • Announcement

$TMO announced the election of Dion Weisler to its BoD, effective March 01, 2017. With this appointment the total number of $TMO board members has reached 12.

$TMO {{ '2017-02-28T21:34:50+0000' | timeago}} • Announcement

$TMO's BoD declared a quarterly cash dividend of $0.15 per share. The dividend will be paid on April 17, 2017 to shareholders of record on March 15, 2017.

$TMO {{ '2017-02-13T14:33:00+0000' | timeago}} • Announcement

$TMO said that its pending acquisition of Finesse Solutions Inc. has received early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. $TMO expects to complete the acquisition in the coming days. The business will be integrated into $TMO's Life Sciences Solutions Segment.

$TMO {{ '2017-01-31T20:18:41+0000' | timeago}} • Webcast

For 2017, $TMO expects to deliver $19.38-19.62Bil in revenue, which would result in 6-7% growth over 2016. Adjusted EPS is expected to be $9.06-9.24, which would lead to 10-12% growth over 2016. Organic revenue growth is expected to be 4% for 2017.

$TMO {{ '2017-01-31T20:17:10+0000' | timeago}} • Webcast

In 4Q16, in $TMO’s Life Sciences Solutions segment, reported revenue increased 10%. In the Analytical Instruments segment, reported revenue increased 32%. In the Specialty Diagnostic segment, reported revenue decreased 4%. In the Laboratory Products and Services segment, reported revenue decreased 3%.

$TMO {{ '2017-01-31T11:48:43+0000' | timeago}} • Announcement

$TMO reported a rise in 4Q16 earnings driven by higher revenue as well as income tax benefit during the latest quarter. Net income rose to $629.5MM or $1.59 per share from $602.6MM or $1.50 per share last year. Revenue grew to $4.95Bil from $4.65Bil. Adjusted EPS increased to $2.41 from $2.12.

$TMO {{ '2016-11-29T15:12:28+0000' | timeago}} • Announcement

$TMO has agreed to acquire MTI-GlobalStem, a private company that develops technology for stem cell research applications. The transaction will be completed after receipt of all required regulatory approvals and as per the agreement, no further details are being provided. MTI-GlobalStem will become part of $TMO’s life sciences solutions segment.

$TMO {{ '2016-11-14T17:31:06+0000' | timeago}} • Announcement

$TMO filed the final module of a premarket approval (PMA) application with the U.S. Food and Drug Administration (FDA) for its Oncomine Universal Dx Test, a multi-gene, next-generation sequencing (NGS)-based assay for non-small cell lung cancer (NSCLC).

Recent Transcripts

SWK (Stanley Black & Decker, Inc.)
Monday, July 24 2017 - 12:00pm
SNA (Snap-on Incorporated)
Thursday, July 20 2017 - 2:00pm
DHR (Danaher Corp.)
Thursday, July 20 2017 - 12:00pm
AA (Alcoa Inc.)
Wednesday, July 19 2017 - 9:00pm
A (Agilent Technologies Inc.)
Monday, May 22 2017 - 8:30pm
UQM (UQM Technologies Inc.)
Thursday, May 11 2017 - 8:30pm
VRML (Vermillion, Inc.)
Thursday, May 11 2017 - 12:30pm
MTD (Mettler-Toledo International Inc.)
Thursday, May 4 2017 - 9:00pm
HII (Huntington Ingalls Industries, Inc.)
Thursday, May 4 2017 - 1:00pm
MTD (Mettler-Toledo International Inc.)
Thursday, May 4 2017 - 12:00pm
LBY (Libbey Inc.)
Tuesday, May 2 2017 - 3:00pm
CGNX (Cognex Corporation)
Monday, May 1 2017 - 9:00pm
GM (General Motors Company)
Friday, April 28 2017 - 2:00pm
ROP (Roper Technologies, Inc.)
Friday, April 28 2017 - 12:30pm
SNE (Sony Corporation)
Friday, April 28 2017 - 8:15am
ABAX (Abaxis, Inc.)
Thursday, April 27 2017 - 8:15pm
APH (Amphenol Corporation)
Wednesday, April 26 2017 - 5:00pm
TMO (Thermo Fisher Scientific, Inc.)
Wednesday, April 26 2017 - 12:30pm
ILMN (Illumina Inc.)
Tuesday, April 25 2017 - 9:00pm
CAT (Caterpillar Inc.)
Tuesday, April 25 2017 - 3:00pm

AlphaGraphics you may like